

## TEMPORARY 3% ALOXI DISCOUNT FOR OA MEMBERS

MGI PHARMA, INC. ("MGI") is pleased to offer the following temporary **Aloxi® (palonosetron HCl)** discount to Oncology Associates members who are currently at the twelve (12%) percent Additional Discount contract pricing tier.



For a limited period (March 12, 2007–September 30, 2007), OA Members who are currently at the twelve (12%) percent Additional Discount contract price for Aloxi, will receive an additional three (3%) percent off their current contract price. The three (3%) percent discount will be in lieu of the Bonus Rebate the Member is eligible for under the Agreement between MGI and Oncology Associates.

**Aloxi Additional 3% Discount Period (temporary): March 12, 2007–September 30, 2007.**

Product	Additional Discount Pricing Tier	Temporary Discount % to Contract Price
Aloxi® 0.25mg/5ml	12% discounted contract price (MGI 206-2)	3%*

\*replaces the Bonus Rebate for the period indicated above

If after the current semi-annual measurement period (October 2006–March 2007, effective May 1st, 2007) a Member moves to a lower tier (Base Contract Price or 6% discounted Contract Price), they will no longer receive the 3% upfront price discount. However, the Member will be eligible for the three (3%) percent in the form of a Bonus Rebate starting May 1, 2007 and ending September 30, 2007.

Please note, the annual 5% rebate is still valid if you are at 70% Market Share for the annual term of the agreement (October 1, 2006– September 30, 2007, with vials purchased during the period September 12–30, 2006 grandfathered into the period for market share calculations).

Please contact Oncology Associates at **888-732-7352** with questions regarding this program.

## PHARMION AGREEMENT EXTENSION

Oncology Associates' agreement with Pharmion for Vidaza (azacitidine for injectable suspension) and Innohep (tinzaparin sodium for injection) has been extended through August 31, 2008. These products will continue to be available to all OA Members in good standing.



Vidaza is available in 100 mg vials and is indicated for the treatment of all five Myelodysplastic Syndrome (MDS) subtypes. Innohep is a once-daily low molecular weight heparin for the treatment of acute symptomatic deep vein thrombosis (DVT) with or without pulmonary embolism when administered in conjunction with warfarin sodium (such as Coumadin).

Innohep and Vidaza are currently available through FloridaInfusion Services. Contact FIS directly at **800-624-0152** to place an order. For more information on Vidaza and Innohep, visit Pharmion's web site at **pharmion.com** or contact Pharmion directly for complete prescribing information at **1-866-PHARMION**. Please call Oncology Associates at **888-732-7352** with any questions regarding this agreement.

## ORTHO BIOTECH AGREEMENT RENEWED

Oncology Associates is pleased to announce that our agreement for Procrit (Epoetin alfa) and DOXIL (doxorubicin HCl liposome injection) has been renewed with Ortho Biotech. The agreement runs from **May 1, 2007 through April 30, 2010** and offers a **1% discount on purchases of Procrit and DOXIL**. This discount is available to all OA Members in good standing. Please contact OA at **888-732-7352** with questions regarding this agreement.

